All In Biotech

Drug Trial Radar · NCT05938465

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The "PROF" Study.

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 6, 2023

Primary completion

May 31, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Exegi Pharma, LLCIndustry
Sponsor type
Industry
Collaborators
The Emmes Company, LLC
First posted
Jul 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.

Conditions

  • Ileal Pouch

Interventions

  • EXE-346Biological

    EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.

  • PlaceboOther

    Placebo contains excipients maltose and silicon dioxide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Incidence, Severity, Relatedness, and Frequency of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)Time frame: 4 weeks
  2. Phase 1b: Number of Participants with Abnormal Physical ExaminationsTime frame: 4 weeks
  3. Phase 1b: Number of Participants with Abnormal Vital SignsTime frame: 4 weeks
  4. Phase 1b: Number of Participants with Abnormal Safety LabsTime frame: 4 weeks
  5. Phase 1b: Study Treatment Discontinuation Due to Treatment Emergent Adverse Events (TEAEs)Time frame: 4 weeks
  6. Phase 2: Incidence, Severity, Relatedness, and Frequency of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)Time frame: 8 weeks
  7. Phase 2: Number of Participants with Abnormal Physical ExaminationsTime frame: 8 weeks
  8. Phase 2: Number of Participants with Abnormal Vital SignsTime frame: 8 weeks
  9. Phase 2: Number of Participants with Abnormal Safety LabsTime frame: 8 weeks
  10. Phase 2: Study Treatment Discontinuation Due to Treatment Emergent Adverse Events (TEAEs)Time frame: 8 weeks
  11. Phase 2: Change in Total Daily Bowel Movement FrequencyTime frame: 8 weeks
  12. Phase 2 Open Label: Incidence, Severity, Relatedness, and Frequency of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)Time frame: 8 weeks
  13. Phase 2 Open Label: Number of Participants with Abnormal Physical ExaminationsTime frame: 8 weeks
  14. Phase 2 Open Label: Number of Participants with Abnormal Vital SignsTime frame: 8 weeks
  15. Phase 2 Open Label: Number of Participants with Abnormal Safety LabsTime frame: 8 weeks
  16. Phase 2 Open Label: Study Treatment Discontinuation Due to Treatment Emergent Adverse Events (TEAEs)Time frame: 8 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Mayo Clinic - Florida (Inflammatory Bowel Disease Center)

    Jacksonville, Florida · Recruiting

  • Corewell Health

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic Department of Gastroenterology

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Penn State Health (Milton S. Hershey Medical Center)

    Hershey, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.